Ro vs iV.im: GLP-1 Telehealth Provider Comparison

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ro and iV.im have emerged as two prominent telehealth platforms offering GLP-1 access, yet they operate under distinctly different clinical and business models. Ro focuses on branded medications with rapid online consultations, while iV.im emphasizes IV-based peptide therapies and comprehensive metabolic profiling. Both claim to streamline access, but clinical differences—including consultation depth, medication formulation, and monitoring protocols—meaningfully affect patient outcomes.

When evaluating telehealth providers for GLP-1 therapy, understanding these distinctions matters. Ro vs iV.im represents more than a brand choice; it reflects different philosophies about consultation rigor, medication type, and personalization. PlexusDx takes a precision-wellness approach: compounded GLP-1 medications paired with optional genetic testing to support informed, provider-led decisions about which peptide pathway may align best with your metabolic profile.

Ro: Branded GLP-1 Access and Rapid Consultation

Ro operates a streamlined, app-based model centered on branded GLP-1 medications such as Ozempic, Wegovy, and Mounjaro. Consultations typically occur via video or messaging with licensed physicians or nurse practitioners, often within hours. Ro's pricing transparency and subscription model appeal to patients seeking convenience; however, consultation duration is frequently brief, limiting deep metabolic assessment.

Ro's clinical strength lies in medication brand familiarity and established dosing protocols. The platform handles pharmacy logistics, reducing patient friction. Notably, Ro operates through partnerships with both traditional and specialty pharmacies. For patients already confident in their GLP-1 choice or seeking rapid access, Ro minimizes administrative barriers. Yet shorter consultations may not explore individual metabolic nuances or genetic predispositions affecting response.

iV.im: Peptide Protocols and Metabolic Profiling

iV.im positions itself as a peptide-focused telehealth platform emphasizing IV administration and comprehensive metabolic workup. The platform typically requires more extensive initial assessment, including bloodwork review and metabolic panels. iV.im's model centers on peptide compounds and proprietary protocols, often bundling laboratory testing with provider consultations to create a more holistic evaluation.

iV.im's clinical differentiation rests on deeper personalization through biomarker context and IV delivery, which some patients prefer for absorption certainty. Consultation times are generally longer, allowing providers to discuss metabolic history, lifestyle, and individual factors. However, this depth comes with higher costs and longer approval timelines compared to Ro's rapid-access model. Patient suitability depends on comfort with IV administration and willingness to invest in comprehensive baseline testing.

Direct Comparison: Platform, Clinical, and Access Factors

Ro and iV.im differ substantially in medication type, delivery method, consultation structure, and cost. The table below summarizes key clinical and operational distinctions to help contextualize your evaluation. Note that individual experiences vary; clinical appropriateness depends on your medical history, GLP-1 history, and provider recommendation.

Factor	Ro	iV.im
Primary Medication Type	Branded GLP-1s (Ozempic, Wegovy, Mounjaro)	Peptide compounds; IV and subcutaneous options
Delivery Route	Subcutaneous injection (patient-administered)	IV infusions or subcutaneous injection
Consultation Duration	Typically 15–30 minutes; messaging-based follow-up	Initial 45–90 minutes; comprehensive assessment
Baseline Testing Required	Minimal; often relies on existing labs	Comprehensive metabolic panel and biomarker review
Estimated Monthly Cost	$150–$400+ depending on medication and tier	$250–$500+ including IV administration and labs
Approval Timeline	Often same-day or next-day consultation	5–10 business days for full assessment
Geographic Availability	All 50 U.S. states	Limited to certain states; IV requires local clinic partnerships
Ongoing Monitoring	Provider check-ins; patient-driven reporting	Scheduled follow-ups with metabolic re-assessment

Clinical Evidence: What Consultation Models Support Better Outcomes?

Research on telehealth GLP-1 efficacy shows that rapid access improves medication initiation rates, yet consultation depth correlates with adherence and side-effect management. A 2023 meta-analysis in *Obesity* noted that brief consultations reduced dropout, while comprehensive assessments enhanced personalization and dose optimization. Neither model is universally superior; outcome depends on patient preparation, baseline health, and medication history.

Ro's rapid-access strength shines for GLP-1-experienced patients or those with straightforward health profiles. iV.im's deeper assessment benefits patients with complex metabolic histories, prior medication intolerance, or those seeking biomarker-informed dosing. Clinical guidance emphasizes that the *appropriate* model matches the individual's clinical complexity and readiness for medication. Asking your provider which model aligns with your specific health context is essential.

Safety, Eligibility, and Contraindications

Both Ro and iV.im require physician screening for GLP-1 contraindications: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, diabetic retinopathy, and severe renal impairment. Ro's brevity sometimes limits deep history-taking; iV.im's extended consultation reduces missed red flags. However, telehealth cannot replace in-person evaluation for complex conditions, and both platforms advise primary-care coordination.

Eligibility criteria differ: Ro accepts patients with BMI ≥27 with comorbidities or BMI ≥30 regardless; iV.im often requires more intensive baseline metabolic data. Side-effect monitoring is critical; Ro patients typically manage symptoms via app messaging, while iV.im schedules structured follow-ups. Nausea, constipation, and dehydration are common early adverse effects. Speak with your chosen provider about their protocol for dose adjustment if side effects emerge or therapeutic goals plateau.

How PlexusDx Supports a More Personalized Approach

Individual variation in GLP-1 response is partly rooted in genetic predispositions affecting peptide pathways. Key variants in genes such as GLP1R, GIPR, and FTO influence baseline appetite regulation, incretin sensitivity, and metabolic rate. While genetic testing cannot predict exact medication response, it may help provide context for why some patients achieve rapid weight loss while others plateau earlier or experience differential side effects.

PlexusDx offers the Precision Peptide Genetic Test ($99 add-on or $298 standalone), which screens for predispositions in GLP-1R, GIPR, FTO, and MC4R genetic pathways. This test is designed to complement—not replace—clinical assessment. When shared with your provider (whether you choose Ro, iV.im, or another platform), genetic insights can support a more informed conversation about medication selection, expected timeline, and monitoring priorities. Note: the test reveals predispositions in peptide genetic pathways, not pharmacogenomic drug metabolism.

PlexusDx compounded GLP-1 options (semaglutide from $179/mo, tirzepatide from $229/mo, or our microdose protocol at $129/mo) offer an alternative pathway that integrates with your chosen provider's protocols. Whether you ultimately work with Ro, iV.im, or a local physician, having a precision-informed discussion about your genetic predispositions and cost constraints ensures your telehealth choice aligns with your clinical and financial reality.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the key difference between Ro and iV.im's consultation models?

Ro emphasizes rapid, brief consultations with branded GLP-1 access; iV.im prioritizes extended, comprehensive assessment with metabolic profiling. Neither is universally better—appropriateness depends on your clinical complexity and timeline.

Does iV.im's IV delivery offer clinical advantages over Ro's injections?

IV administration may improve absorption certainty and reduce injection anxiety for some patients. However, clinical efficacy of GLP-1 is comparable regardless of subcutaneous vs. IV delivery. IV requires local clinic logistics; subcutaneous offers home convenience.

How much does each platform cost monthly?

Ro ranges $150–$400+ depending on medication tier. iV.im typically costs $250–$500+ including IV administration and labs. PlexusDx compounded GLP-1 starts at $129/mo (microdose), $179/mo (semaglutide), or $229/mo (tirzepatide).

Can I use my genetic test results with Ro or iV.im?

Yes. PlexusDx's Precision Peptide Genetic Test ($99 add-on or $298 standalone) reveals predispositions in peptide pathways. Share results with your Ro or iV.im provider to inform personalized consultation and medication decisions.

Which platform is safer for complex medical histories?

iV.im's longer consultation and metabolic assessment reduce missed contraindications. However, both platforms require primary-care coordination and cannot replace in-person evaluation for serious comorbidities. Discuss your full medical history openly with your chosen provider.

Ro vs iV.im: Clinical Models for GLP-1 Telehealth Access